Loading...
Loading...
Browse all stories on DeepNewz
VisitHow will Quanterix's market valuation change post-Akoya acquisition by end of 2025?
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Stock market data and financial reports
Quanterix to Acquire Akoya Biosciences in All-Stock Deal for First Integrated Solution in Ultra-Sensitive Biomarker Detection
Jan 10, 2025, 11:37 AM
Quanterix Corporation has reached an agreement to acquire Akoya Biosciences in an all-stock transaction. This merger aims to create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, enhancing capabilities in disease detection at various stages. Both companies are recognized for their contributions to life sciences, with Quanterix focusing on advanced biomarker detection technologies and Akoya specializing in spatial biology solutions. The deal is expected to combine their strengths and improve diagnostic capabilities in the healthcare sector.
View original story
Decrease by 0-20% • 25%
Increase by 0-20% • 25%
Increase by more than 20% • 25%
Decrease by more than 20% • 25%
50% to 70% • 25%
Less than 30% • 25%
More than 70% • 25%
30% to 50% • 25%
Stock price decreases • 25%
Stock price changes by less than 10% • 25%
Stock price increases by 10-20% • 25%
Stock price increases by more than 20% • 25%
Stock declines more than 10% • 25%
Stock remains flat or declines 0-10% • 25%
Stock rises 0-10% • 25%
Stock rises more than 10% • 25%
Increase by less than 20% • 25%
Decrease • 25%
No change • 25%
Increase by 20% or more • 25%
No • 50%
Yes • 50%
Less than $50 billion • 25%
$50 billion to $60 billion • 25%
$60 billion to $70 billion • 25%
More than $70 billion • 25%
Less than $15 billion • 25%
More than $25 billion • 25%
$15 billion to $20 billion • 25%
$20 billion to $25 billion • 25%
Significant increase in revenue • 25%
Decrease in revenue • 25%
No significant change • 25%
Moderate increase in revenue • 25%
Negative • 25%
Unchanged • 25%
Positive • 25%
Neutral • 25%
$3 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
Less than $3 billion • 25%
Over $10 billion • 25%
No • 50%
Yes • 50%
2-3 • 25%
4 or more • 25%
0 • 25%
1 • 25%